Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 14 May 2024

The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Tuesday, 14 May 2024 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed at the Meeting include the following.
 
Income statement and balance sheet as well as consolidated income statement and balance sheet
It was resolved to adopt the income statement and balance sheet, as well as the consolidated income statement and balance sheet, included in the Company’s annual report.
 
It was resolved, pursuant to the proposal from the Board of Directors, that the total profits of SEK 328,371,058.00 available to the Annual General Meeting should be carried forward.
 
The Board of Directors and Auditor
It was resolved to discharge the members of the Board of Directors and the Chief Executive Officer from liability in relation to their management of the Company’s operations during the period covered by the audit report.
 
It was resolved that the number of members of the Board of Directors appointed by the Annual General Meeting shall be five. It was resolved that the number of auditors should continue to be one.
 
For the period until the end of the next Annual General Meeting, Mia Arnhult, Lars Höckenström, Fredrik Dahl and Pia Gideon were re-elected as members of the Board of Directors. Thomas Eklund was elected as new member of the Board of Directors for the same period.
 
For the period until the end of the next Annual General Meeting, Mia Arnhult was re-elected as Chairman of the Board of Directors. It was resolved to, for the period until the end of the next Annual General Meeting, elect the auditing firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. It was noted that the authorized public accountant Magnus Lagerberg would be auditor-in-charge.
 
Fees to the Board of Directors and the Auditor
It was resolved to approve the fees to the Board of Directors as proposed by the Nomination Committee, entailing a fee of SEK 379,500.00 to the Chairman and a fee of SEK 178,000.00 to each of the other members of the Board of Directors, amounting to a total fee of SEK 1,269,500.00. The Annual General Meeting further resolved that a member of the Board of Directors who is also the Chairman of the Audit Committee shall be entitled to an additional fee of SEK 60,000.00, and a member of the Board of Directors who is also a member of the Audit Committee shall be entitled to an additional fee of SEK 20,000.00.
 
The Annual General Meeting approved the Nomination Committee’s proposal that the auditor’s fee shall be paid according to an approved invoice.
 
Authorization for the Board of Directors to resolve upon share issues
It was resolved, in accordance with the Board of Director’s proposal, to authorize the Board to resolve upon issues of shares and other financial instruments – with deviation from the shareholders’ preferential rights – to facilitate financing of the operations, corporate acquisitions and broadening the shareholder base.
 
Establishment of employee stock option program and issue of warrants
It was resolved, in accordance with the Board of Directors’ proposal, to establish an employee stock option program for current and future employees and other key people in the Company and its subsidiaries. It was further resolved, in accordance with the Board of Directors’ proposal, upon a directed issue of not more than 262,840 warrants, in order to facilitate the Company’s delivery of shares under the employee stock option program.

For more information, please contact:
Fredrik Alpsten, CEO 
Email: [email protected] 
Telephone: +46 70 667 31 06
 
Sabina Berlin, CFO 
Email: [email protected] 
Telephone: +46 739 51 95 02

About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB. 

For more information, visit www.devyser.com.